Maxcyte Inc (MXCT) financials
Maxcyte revenue and earnings by year
Maxcyte's revenue was $33.0 million in the fiscal year to December 31, 2025, down 14.5% from the year before. Net income was -$44.6 million, -135.1% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 7.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 33 | 39 | 41 | 44 | 34 | 26 | 22 |
| Revenue growth | -14.5% | -6.4% | -6.7% | 30.6% | 29.5% | 21.0% | — |
| Gross profit | 27 | 32 | 37 | 39 | 30 | 23 | 19 |
| Gross margin | 81.2% | 81.6% | 88.5% | 88.5% | 89.2% | 89.4% | 88.4% |
| Operating income | -52 | -51 | -48 | -27 | -18 | -11 | -12 |
| Operating margin | -157.1% | -132.5% | -117.0% | -61.8% | -53.7% | -42.3% | -57.4% |
| Net income | -45 | -41 | -38 | -24 | -19 | -12 | -13 |
| Net margin | -135.1% | -106.3% | -91.8% | -53.3% | -56.3% | -45.2% | -59.6% |
| Diluted EPS | -$0.42 | -$0.39 | -$0.37 | -$0.23 | -$0.21 | -$0.17 | — |
| Free cash flow | -36 | -29 | -25 | -33 | -15 | -11 | -10 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open MXCT in Markets.
How Maxcyte makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $4.10M | 56.4% |
| License | $2.59M | 35.6% |
| Assay & Other Service Revenue | $583K | 8.0% |
See also: MXCT returns
No forecast, no recommendation. This page describes Maxcyte Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.